REDWOOD CITY, Calif., Aug. 4, 2011 /PRNewswire/ -- Genomic Health , Inc. (Nasdaq: GHDX ) today announced that Dean Schorno, Genomic Health's Chief Financial Officer, will present at the 31st Annual Canaccord Genuity Growth Conference in Boston on Thursday, August 11, 2011 at 11:30 a.m. Eastern Time (ET).
To access the live and subsequently archived webcast of the presentation, visit the Investor Relations section of Genomic Health's website at http://investor.genomichealth.com . Please connect to the website at least 15 minutes prior to the beginning of the presentation to allow for any necessary software downloads. An archived replay will be available for three months beginning 24 hours after the live presentation.
About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX ) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multigene expression test developed for the assessment of risk of recurrence in patients with stage II disease. As of March 31, 2011, more than 10,000 physicians in over 60 countries had ordered more than 200,000 Oncotype DX tests. Genomic Health has a robust pipeline focused on developing tests to optimize the treatm